Monday, July 27, 2020

Avidity Biosciences Names Chief Medical Officer

San Diego-based Avidity Biosciences, a developer of biopharmaceuticals in the area of RNA-targeted therapeutics, has named Jae Kim, M.D., as the company's Chief Medical Officer. Kim was previously Clinical Research Head, Chair of the Clinical Trial Review Board, and Vice President of Clinical Development at Alnylam Pharmaceutics. He also has served at MyoKardia and Amgen. Avidity Biosciences said that Dr. Kim will be responsible for leading and expanding Avidity's Antibody Oligonucleotide Conjugate pipeline and will serve as a key member of its executive management team.